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Abstract
In colorectal cancer, oncogenic mutations transform a hierarchically
organized and homeostatic epithelium into invasive cancer tissue
lacking visible organization. We sought to define transcriptional
states of colorectal cancer cells and signals controlling their develop-
ment by performing single-cell transcriptome analysis of tumors and
matched non-cancerous tissues of twelve colorectal cancer patients.
We defined patient-overarching colorectal cancer cell clusters char-
acterized by differential activities of oncogenic signaling pathways
such as mitogen-activated protein kinase and oncogenic traits such
as replication stress. RNA metabolic labeling and assessment of RNA
velocity in patient-derived organoids revealed developmental trajec-
tories of colorectal cancer cells organized along a mitogen-activated
protein kinase activity gradient. This was in contrast to normal colon
organoid cells developing along graded Wnt activity. Experimental
targeting of EGFR-BRAF-MEK in cancer organoids affected signaling
and gene expression contingent on predictive KRAS/BRAF mutations
and induced cell plasticity overriding default developmental trajec-
tories. Our results highlight directional cancer cell development as a
driver of non-genetic cancer cell heterogeneity and re-routing of
trajectories as a response to targeted therapy.
Keywords cancer profiling; ERK; RNA velocity; single-cell RNA sequencing;
SLAM-Seq
Subject Categories Cancer; Digestive System
DOI 10.15252/emmm.202114123 | Received 11 February 2021 | Revised 27 July
2021 | Accepted 30 July 2021
EMBO Mol Med (2021) e14123
Introduction
Healthy cells in the human body develop along trajectories
controlled by intrinsic and extrinsic signals to ensure tissue home-
ostasis. Cancer cells cannot maintain homeostasis, as oncogenic
mutations activate signaling pathways cell-intrinsically and render
cancer cells unresponsive to paracrine signals (Hanahan & Wein-
berg, 2011). Colorectal cancer (CRC) commonly initiates via muta-
tions activating Wnt/b-catenin signaling that maintains stem cells in
the normal colon epithelium (Fearon, 2011). Subsequent mutations
deregulate further signaling pathways such as RAS-RAF-MEK-ERK
(also known as mitogen-activated protein kinase; MAPK signaling)
providing pro-proliferative cues. Less frequently, CRC initiates via
BRAF mutations or from chronic inflammation (Lasry et al, 2016;
De Palma et al, 2019). Genetic CRC drivers have direct and indirect
effects on cancer cell development and the cellular composition of
CRC and its microenvironment.
There is substantial evidence for the existence of tumor cell
subpopulations and clonal architecture in CRC depending on genet-
ics, microenvironmental cues, and space constraints (Van Der Heij-
den et al, 2019). Cancer stem cells are defined by their capacity for
self-renewal and ability to initiate clonal outgrowth (Kreso & Dick,
2014). CRC cells with these characteristics have been distinguished
by surface proteins like CD133, EPHB2, or LGR5 (O’Brien et al,
2007; Ricci-Vitiani et al, 2007; Merlos-Suarez et al, 2011). Likewise,
lineage tracing in CRC cancer models has revealed preferential
outgrowth of cancer cell subpopulations defined by expression of
genes such as LGR5 or IL17RB (Shimokawa et al, 2017; Goto et al,
2019) or by localization at the leading edge of the tumor (Lamprecht
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et al, 2017). Furthermore, CRC cells located at the invasive front
and expressing genes such as the matrix metalloproteinase gene
MMP7 contributed disproportionally to metastasis (Brabletz et al,
1999; Vermeulen et al, 2010). While these studies suggest that CRC
cells are heterogeneous and hierarchically organized, other studies
stress that developmental capacities of CRC cells are subject to a
high degree of plasticity. In particular, oncogenic mutations and
paracrine signals have been shown to trigger reversal of develop-
mental trajectories so that differentiated cells regain stem cell char-
acteristics (Buczacki et al, 2013; Schwitalla et al, 2013; Jadhav
et al, 2017).
Metastatic CRC is treated by chemotherapy and/or therapies
targeting MAPK signaling, depending on predictive mutation status.
Patients without RAS or RAF mutations profit from anti-EGFR anti-
body therapy (Karapetis et al, 2008; Van Cutsem et al, 2009), while
patients with BRAF-mutant CRC now receive first-line therapy
combinations of anti-EGFR antibodies and BRAF kinase inhibitors
(Corcoran et al, 2018). Recent studies suggest roles for cell plasticity
in therapy resistance. For instance, chemoresistance has been linked
to subpopulations of CRC cells expressing the transcription factor
ZEB2 (Francescangeli et al, 2020), and anti-EGFR therapy resistance
has been associated with rise of stem cell-like populations (Lupo
et al, 2020) and stromal remodeling (Woolston et al, 2019).
Taken together, emerging evidence suggests that hierarchically
organized tumor cell heterogeneity and cell plasticity play key roles
in CRC progression and therapy response. However, developmental
states of CRC cells are not well-defined, and it is not known whether
transcriptome states are graded along preferential developmental
trajectories. Here, we use single-cell RNA sequencing to identify
patient-overarching CRC cell states defined by strengths of onco-
genic signals and replicative responses. We use metabolic labeling
of RNA in CRC organoids to delineate CRC development and show
that CRC cell differentiation states, developmental trajectories, and
therapy-associated cell plasticity are informed by MAPK activity.
Results
CRC cells can assume patient-overarching states
To capture the diversity of CRC cell states compared to the normal
colon epithelium, we performed single-cell transcriptome analysis of
twelve previously untreated CRC patients undergoing primary
surgery (Fig 1A). We utilized tissue samples that included the inva-
sive tumor front and matched non-cancerous tissues (Appendix Fig
S1). Tumors encompassed stages pTis (Tumor in situ) to pT4, with
or without metastasis, and with various locations along the cephalo-
caudal axis of the colon (Table EV1). Genetic analysis revealed
mutational patterns characteristic for canonical CRC progression in
most tumors; however, tumors from patients P007, P014, P020, and
P026 contained the BRAFV600E mutation often associated with the
serrated progression pathway and tumor P008 was colitis-associated
(Tables EV1 and EV2). Eleven patients were diagnosed with
microsatellite-stable (MSS) CRC, while the tumor of patient P026
was microsatellite-instable (MSI). We produced transcriptome
libraries using a commercial droplet-based system and sequenced
the libraries to obtain transcriptomes covering 500–5,000 genes per
cell. Transcriptomes were clustered, and clusters were allocated to
epithelial, immune, or stromal subsets, using known marker genes
(Smillie et al, 2019) (Fig 1B, Appendix Fig S2, Table EV3), and more
than 30,000 epithelial cell transcriptomes were analyzed further.
Normal and tumor-derived epithelial cell transcriptomes of all
patients largely intermingled when visualized in a common Uniform
Manifold Approximation Projection (UMAP) employing ten princi-
pal components (McInnes et al, 2018), but partially separated when
using a higher number of 50 components for UMAP embedding
(Fig 1C). Separation by patient occurred particularly in areas
enriched for tumor-derived transcriptomes suggesting the existence
of patient-specific gene expression in cancer epithelium. In
summary, the UMAP embedding indicates that our single-cell data
are largely free from sample-specific bias, but instead reflect intrin-
sic differences between normal and tumor cell transcriptomes.
We used cell type-specific signatures and marker genes to anno-
tate the epithelial cell clusters (Smillie et al, 2019; Fig 1D and E;
Tables EV3 and EV4). In the normal epithelium, we identified stem
cells by markers such as LGR5 and OLFM4. Neighboring clusters
were annotated as enterocyte progenitors or mature enterocytes by
expression of absorptive lineage markers including KRT20 and
FABP1 (Appendix Fig S3, Table EV4). BEST4- and OTOP2-
expressing enterocytes formed a discrete cluster (Parikh et al,
2019). Further separate epithelial clusters were identified as imma-
ture and mature secretory goblet cells expressing MUC2 and TFF3,
and as tuft cells expressing TRPM5. Four clusters formed largely
from tumor cell transcriptomes, termed TC1-TC4. These clusters
were defined by high, but also unequal, levels of stem cell markers
such as OLFM4, CD44, and EPHB2 and DNA repair genes such as
XRCC2. MMP7 was among the few genes expressed exclusively in
cancer, but not in the normal epithelium (Appendix Fig S3). Clus-
ters populated by differentiated absorptive and secretory cells were
reduced in tumors, and profiles representing tuft cells and BEST4/
OTOP2-positive enterocytes were vastly underrepresented.
Microsatellite-stable CRC is defined by somatic copy number
aberrations (SCNAs). Thus, we next distinguished cancer from
normal epithelial transcriptomes derived from the tumor tissues by
inferring SCNAs. We identified clusters of SCN-aberrant epithelial
cells in ten out of twelve tumors (Figs 1F and Fig EV1A). Exome
sequencing of tumors P007, P008, and P009 validated SCNA calling
from transcriptomes, showing that the procedure is robust for our
single-cell data (Fig EV1B). P014 and P026 contained no cells with
overt SCNAs. This was expected for tumor P026, which is MSI, but
unexpected for P014, which was diagnosed as BRAF-mutant,
however MSS. In-depth analysis of patient-specific gene expression
patterns (Appendix Fig S4A) and protein distributions
(Appendix Fig S4B) revealed that patient-specific differences in
cancer cell transcriptomes are at least partly driven by individual
patterns of genomic gains and losses (Appendix Fig S4C–E).
More than 86% of the TC1-4 cells were called SCN-aberrant,
along with substantial fractions of cells defined as stem/transient-
amplifying (TA)-cell-like (36%) or immature goblet cells (22%,
Fig 1F and G, and Fig EV2 for data by patient, Table EV5). In
contrast, a large majority (95%) of mature absorptive enterocytes
and mature goblet cells derived from tumor samples were identified
as copy number normal and therefore likely stem from non-
cancerous tissue at the tumor margins. In summary, our analyses
define six main patient-overarching clusters of CRC cells: CRC cells
resembling normal stem/TA-cell-like cells, CRC cells resembling
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Figure 1. Generation of CRC single-cell RNA sequencing data and epithelial cell type census.
A Workflow of the Clinical Single Cell Sequencing pipeline. In short, CRC and adjacent non-tumor tissue were sampled from 12 patients. Single-cell RNA sequencing
data were generated using the 10× Genomics platform, as outlined in Materials and Methods. For histology, see Appendix Fig S1. For patient characteristics, see
Table EV1, for mutational data, see Table EV2.
B–D UMAPs of single-cell transcriptome data. (B) UMAPs of epithelial, immune, and stromal cell transcriptomes, color-coded by tissue origin as assessed by marker
genes. For marker genes, see Table EV3. (C) UMAPs of epithelial cell transcriptomes, color-coded by patient identity or tissue of origin, as indicated. (D) UMAPs of
epithelial cells, separated by tissue of origin (normal vs. tumor). Clusters are color-coded by cell identity, as inferred from marker genes as outlined in main text.
For epithelial cell cluster marker genes, see Table EV4.
E Relative fractions of epithelial cell states for all patients.
F Identification of copy number-aberrant versus normal epithelial cells in tumor tissue. To the left: Cell cluster dendrogram, color-coded by patient and by copy
number-associated clusters (n = 2 per patient, copy number normal cluster: gray; copy number-aberrant cluster: red). To the right: Localization of SCN-aberrant
cells in the UMAP (red).
G Relative fractions of epithelial cell states for SCN-normal versus SCN-aberrant cells for all patients. For fractions by patient and copy number status, see Fig EV2.
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immature goblet-like cells, and CRC cells in the TC1-4 clusters with
transcriptomes distinct from well-defined cell types of the normal
colon epithelium.
Epithelial tumor cell clusters differ by oncogenic traits
and signals
We next defined characteristics of the six CRC cell clusters by
computing relative strengths of transcriptional footprints related to
oncogenic signaling and cancer-associated functional traits, using
transcriptome data of all copy number-aberrant cells (Fig 2A and B).
TC1 and TC4 were significantly enriched for the expression of direct
MAPK/ERK targets (P = 0.004 and P = 0.006, FDR-corrected post
hoc Wilcox tests, respectively; Schubert et al, 2018), across all
tumors and in particular in P007. We furthermore found a strong
association of TC1 cells with the expression of hallmark signatures
related to DNA repair and the G2/M replication checkpoint across all
individual cancers (P = 1.4E-10; Liberzon et al, 2015). This indicates
that TC1 cluster cancer cells experience high levels of replication
stress, a therapy-relevant trait of many cancers, including CRC.
Indeed, TC1 cluster cells were exclusively assigned to the S or G2/M
cell cycle phases by gene expression (Fig 2C), in line with cells under
replication stress, as also seen by XRCC2 expression (Appendix Fig
S3). The DNA damage-associated protein PARP stained many nuclei
of the TC1-high CRC tissue P009 but not of TC1-low P008 (Fig 2D).
Cancer cells clustered in TC4 were characterized by expression of an
intestinal YAP target signature (P = 2.2E-8; Serra et al, 2019). YAP
transcriptional activity is linked to regenerative responses and tumor
progression (Zanconato et al, 2016). TC2 transcriptomes were signif-
icantly associated with high PI3K pathway activity (P = 8.9E-10),
related to control of metabolism and apoptosis. Wnt/b-catenin target
gene activity was high across all TC clusters, but stem/TA-cell-like
cancer cells showed stronger expression of a LGR5-ISC stem cell
signature that is Wnt-driven (Merlos-Suarez et al, 2011; Mu~noz et al,
2012), but this association was not significant across the patients. In
summary, assessment of cell signaling signatures provides informa-
tion on pathway activities of epithelial cancer cell clusters and speci-
fic features of individual tumors. The analyses indicate that
assignment of cancer cell transcriptomes to the TC1-4 clusters
reflects, at least partially, differential states of oncogenic networks
and oncogene-induced functional traits.
We validated our model of six patient-overarching CRC cell states
using single-cell data from Belgian and Korean patient cohorts (Lee
et al, 2020; Qian et al, 2020). We could confirm a prevalence of
TC1-4, stem/TA-cell-like and goblet-cell-like transcriptomes in SCN-
aberrant cancer cells compared to SCN-normal and normal tissue
epithelial cells and verified differential signaling pathway activities
between the clusters (Fig EV3).
CRC developmental trajectories follow a MAPK gradient
Immunofluorescent staining of primary CRC sections with antibodies
directed against the stem cell marker OLFM4, the proliferationmarker
KI67, and the differentiation markers TFF3 and FABP1 revealed cell
heterogeneity, but not how cancer cells in the tissue are related to
each other (Fig EV4). To establish whether CRC cells are hierarchi-
cally organized, we established organoid lines of two tumor samples,
P009 and P013 (Fig 3A). Organoids matched the cancer tissue on a
mutational level (Table EV2). We cultured the cancer organoids,
termed P009T and P013T, as well as normal colon organoids, termed
NCO, in medium containing Wnt, R-Spondin, and EGF (WRE
medium) or alternatively in medium lacking Wnt and R-Spondin (E
medium). NCO organoids cultured in WRE medium showed graded
expression of the intestinal LGR5-ISC stem cell signature, while
expression of differentiation markers was graded in the opposite
direction (Fig 3B). LGR5-ISC signature activity was lost when NCO
organoids were cultured in E medium. In P009T and P013T CRC orga-
noids, LGR5-ISC signature activity was higher and independent of
Wnt/R-Spondin, while expression of differentiation signature genes
was much lower. Taken together, these expression patterns are in line
with Wnt-dependent stem cell maintenance in normal tissue, and
Wnt-independent stem cell maintenance and block of terminal dif-
ferentiation in cancer tissue with APC mutations. The data however
do not showwhether graded developmental trajectories exist in CRC.
We, therefore, metabolically labeled RNAs of the organoids by
4-thio-uridine (4sU), before dissociation and single-cell sequencing
(scSLAM-Seq; Fig 3C; Herzog et al, 2017; J€urges et al, 2018). This
allowed us to distinguish nascent labeled from older non-labeled
mRNA, to order cells along inferred latent time based on dynamic
RNA expression (Bergen et al, 2020), also known as RNA velocity
(Appendix Fig S5 for quality controls). When cultured in WRE
medium, developmental trajectories of normal NCO organoids initi-
ated in areas of maximal LGR5-ISC signature scores and terminated
in a region containing differentiated cells (Fig 3D). When cultured
without Wnt/R-Spondin in E medium, NCO normal colon organoids
lost uniform direction of RNA velocity. In contrast, the P009T and
P013T cancer organoids maintained strong transcriptional trajecto-
ries regardless of Wnt/R-Spondin in the medium.
We ordered organoid transcriptomes along latent time and
assessed strengths of oncogenic signals (Fig 3E). In line with the
key role of Wnt in stem cell maintenance, normal colon organoids
showed a gradient of Wnt/b-catenin target gene expression along
latent time when cultured in WRE medium. In contrast, both P009T
and P013T cancer organoids showed no graded Wnt/b-catenin-
related expression, but a clear gradient of MAPK target gene activity
along latent time in both medium conditions. TFF3, marking secre-
tory differentiation, was graded in CRC organoids along latent time,
but FABP1, marking absorptive differentiation in the normal colon,
was not (Fig 3F), in line with TFF3 marking differentiated goblet-
like CRC cells at the end of developmental trajectories. Proliferation
marker MKI67 was confined to the beginning of the latent time
trajectory of normal organoids in WRE medium and showed
extended gradients in CRC organoids. Both P009T and P013T orga-
noids displayed Wnt-dependent loss of MKI67 expression along
latent time and also Wnt-dependent MMP7 expression. In summary,
our metabolic RNA labeling experiments indicate decreasing MAPK
activity along CRC developmental trajectories and suggest a role for
Wnt as a paracrine signal influencing gene expression, such as
MMP7, in APC-deficient CRC cells.
MAPK target gene expression defines CRC differentiation states
As MAPK-related gene expression was associated with developmen-
tal trajectories in CRC organoids, we analyzed whether the previ-
ously defined states of primary CRC cells were organized along a
MAPK gradient in primary CRC. We assigned the SCN-aberrant
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primary cancer cell transcriptomes to 40 bins along a gradient of
diminishing LGR5-ISC gene signature activity or along decreasing
MAPK activity, and determined expression levels of the stem cell
markers LGR5 and EPHB2 (Merlos-Suarez et al, 2011; Fig 4A). As
expected, ordering transcriptomes by LGR5-ISC signature strength
resulted in graded expression of LGR5 and EPHB2, and the signature
was especially suited for aggregating cells with high LGR5 expres-
sion. However, MAPK target gene signature strength performed
even better in sorting cells along a gradient of EPHB2 expression.
We conclude that expression patterns of known CRC cell hierarchy
markers agree with MAPK-driven development.
When ordering primary CRC transcriptomes along a gradient of
LGR5-ISC activity, a higher proportion of stem/TA-like tumor cells
aggregated at the high end of the gradient, whereas tumor cells
assigned as immature goblet cell-like accumulated in the lower end,
and TC1-4 cells displayed a broad distribution (Fig 4B). In contrast,
ordering of CRC cells by MAPK signature activity significantly
enriched TC1 and TC4 cells at the start of the gradient (P = 8.6E-23
and P = 7.6E-20, respectively, adjusted Pearson’s chi-squared p-
value), whereas stem/TA- and immature goblet cell-like cells
concentrated at the lower end (P = 1.3E-19 and P = 1.1E-8, respec-
tively), and these aggregate differences were also preserved as
graded cell state distributions along the MAPK axis in individual
patients (Fig 4C, Table EV6): P007 showed the highest MAPK activ-
ity, and the highest proportion of TC4 cells which clustered in the




Figure 2. CRC cell clusters are distinguished by signaling pathway activities.
A Transcriptional activity associated with key oncogenic traits and signals, by tumor-specific cell type and patient, as indicated. Red: high activity, blue: low activity.
Significance was assessed by Kruskal–Wallis test (FDR-corrected P < 0.05), followed by a post hoc analysis using a Wilcox test of each group against all other groups,
FDR-corrected significance levels are shown (*P < 0.05; **P < 0.01; ***P < 0.001).
B Visualization of signatures corresponding to oncogenic traits and signals in the tumor cell transcriptome UMAP.
C Cell cycle distribution of TC1-4 epithelial tumor cells, as inferred from single-cell transcriptomes.
D Immunofluorescence of DNA damage-associated nuclear protein PARP. Images show adjacent normal and tumor crypts of tissue P009T, marked by N and T,
respectively, and tumor tissue of patients P008 and P009, as indicated. Scale bar 100 µm. Significance was assessed by an unpaired t-test, after blinded analysis of 10
random images per tumor.
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MAPK activities in most other CRCs, including P008, P012, P013,
and P016. In contrast, stem-/TA-like tumor cells and immature
goblet-like CRC cells displayed relatively low expression of MAPK
targets in all tumors, particularly in P009, P012, P013 P017, P021,
P025, and P008, P017, respectively.
To experimentally determine whether the CRC cell states are
functionally linked to MAPK activity, we blocked MAPK signaling in
CRC organoids by the MEK1/2 inhibitor Selumetinib (AZD6244) or
by Selumetinib in combination with the EGFR inhibitor Sapatinib
(AZD8931) and analyzed singe-cell gene expression after 48 h
(Fig 4D). We found that cells showing a high TC1 signature were
diminished after MEK inhibition in P009T organoids, while the frac-
tion of cells with a high goblet-cell-like signature was increased.
Likewise, P013T organoid cells showed lower expression of the TC4
signature genes after MAPK blockade and higher expression of the
stem cell-related LGR5-ISC signature. These results suggest that CRC
cell states are MAPK-driven.
Targeted therapy alters cell signaling networks in CRC organoids
MAPK is a key target of CRC therapy, as blockade of EGFR is the
first-line therapy for patients with metastasized RAS/RAF-wild-type
CRC, and combined blockade of EGFR and BRAF is first-line therapy
for patients with advanced CRC containing oncogenic BRAF muta-
tions. We therefore asked whether targeted therapy is associated
with changes in CRC cell states and trajectories. In addition to the
RAS/RAF-wild-type organoid lines P009T and P013T, we employed
OT227 and OT302 organoids carrying KRASG13D and KRASG12D
mutations, respectively, and the BRAFV600E-mutant and APC-wt
lines B2040 and C2019 (for panel sequencing, see Table EV2). The
organoid lines exhibited different growth factor dependencies
(Appendix Fig S6), but were uniformly cultured in the presence of
EGF throughout the experiments for comparable results. As the
blockade of EGFR using the antibody cetuximab was not effective
in vitro as also observed by others (Sch€utte et al, 2017), we treated
the organoids with the EGFR inhibitor Sapatinib, the BRAF inhibitor
LGX818 (Encorafenib), the MEK inhibitor Selumetinib and combina-
tions for 48 h, before subjecting single-cell suspensions to CyTOF
and scSLAM-seq (Fig 5A, Appendix Fig S7 for summaries of CyTOF
data) to measure relative activities of signal transducers and related
transcriptional signatures, respectively (Fig 5B).
Inhibitor treatments had variable effects on the cell signaling
network between lines, but we observed communalities between
the lines with shared RAS/RAF mutational status (Fig 5C): In RAS/
RAF-wild-type lines, treatment with EGFR inhibitor reduced both
MEK and ERK phosphorylation. MEK inhibition decreased ERK
phosphorylation, but increased MEK phosphorylation via negative
feedback suppression (Fritsche-Guenther et al, 2011). BRAF inhibi-
tors raised levels of MEK and ERK phosphorylation, suggesting para-
doxical activation of RAF (Hatzivassiliou et al, 2010). In contrast,
the KRAS mutant lines OT227 and OT302 were largely unresponsive
to EGFR inhibition, while MEK inhibition caused strong upregula-
tion of MEK phosphorylation, and BRAF blockade strongly upregu-
lated both MEK and ERK phosphorylation. A similar response to
MEK inhibition was found in the BRAF-mutant lines C0219 and
B2040; however, in these lines BRAF inhibition alone or in combina-
tion with EGFR inhibition resulted in substantial loss of ERK phos-
phorylation.
Cell signaling changes translated into gene expression (Fig 5D),
as we found high correlation between ERK phosphorylation and
MAPK target gene activity (P < 0.0001, using linear models with
line-specific offsets; Fig 5E). Furthermore, across all CRC organoids,
we observed a positive correlation between p-ERK and KI67 protein
levels (P < 0.005) and a negative correlation between p-ERK and
cleaved Caspase3 (P < 0.005) and cleaved PARP levels, in line with
roles of MAPK in activation of proliferation and inhibition of apop-
tosis. Positive correlations also existed between p-ERK and YAP
(P < 0.0001), and between MAPK target expression and YAP target
expression (P < 0.0001). In contrast, MAPK target activity was nega-
tively correlated with Wnt target activity (and P < 0.05, respec-
tively; Fig 5E). A direct interaction between MAPK and YAP
signaling is supported by induction of transgenic BRAFV600E in a
mouse intestinal organoid model (Riemer et al, 2015), which
resulted not only in activation of the MAPK target gene signature,
but also in an even stronger activation of YAP target genes (Fig 5F).
Targeted therapy alters developmental trajectories of CRC
organoid cells
We traced developmental trajectories in the panel of six CRC orga-
noid lines by computing latent time from scSLAM data in the
absence of treatment (DMSO control condition; Fig 6A). In five out
of six organoids, cells at early latent time expressed significantly
higher levels of MAPK targets and TC1 and TC4 signatures, extend-
ing our previous results to lines with mutations in the MAPK path-
way. In contrast, cells at late latent time expressed the Goblet cell
▸Figure 3. RNA metabolic labeling defines tumor cell trajectories in patient-derived organoids.A Phenotypes of patient-derived organoid lines P009T and P013T.
B UMAPs of organoid single-cell transcriptomes. Organoid lines and medium conditions as indicated. LGR5-ISC stem cell, enterocyte, and Goblet cell signatures are
visualized.
C Schematic representation of workflow to infer RNA dynamics (“RNA velocity”). In short, organoids were passaged and assigned to different medium conditions. After
three days, nascent RNA was metabolically labeled for 2 h using 4sU. Organoids were harvested, dissociated, and fixed. RNA in single cells was alkylated, and cells
were subjected to single-cell sequencing. Reads were assigned to nascent or old RNA status, depending on diagnostic T-C mutational status.
D Developmental trajectories inferred from RNA metabolic labeling. Bold and thin arrows indicate high versus low directionality of RNA velocity. Colors below RNA
velocity show latent time (yellow: early latent time; blue: late latent time).
E Activities of Wnt/b-catenin and MAPK target genes in organoid single-cell transcriptomes, ordered along latent time.
F Activities of TFF3, FABP1, MKI67, and MMP7 in organoid single-cell transcriptomes, ordered along latent time.
Data information: Color code for panels E and F: Red: high activity; blue: low activity.
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Figure 4. MAPK activity is linked to CRC cell differentiation states.
A Gene expression of LGR5 and EPHB2, along activity gradients of LGR5-ISC or MAPK target gene signatures.
B Cell state distribution of SCN-aberrant CRC cells along gradients of LGR5-ISC or MAPK transcriptional signatures, as in A.
C Cell state distribution of SCN-aberrant CRC tumor cells along MAPK signature activity, as in B, per tumor. Correlation between cell state distributions and MAPK
target gene was calculated using Pearson’s r. For correlations and significances, see Table EV6. Color code as in Fig 4B.
D UMAP representations of single-cell transcriptomes derived from P009T or P013T organoids, after MAPK blockade using MEK or combined MEK and EGFR inhibition.
Color codes are treatment conditions or expression strength of signature, as indicated. Dashed line in P013T UMAP roughly separates control (DMSO) and MEK/EGFR
inhibitor-treated cells.
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signature, indicating differentiation at trajectory endpoints (for
statistics on cell state signature distributions, see Table EV6). The
stem cell-related LGR5-ISC signature was not uniformly graded
along latent time. The outlier line OT227 did not show clear direc-
tionality of cell development.
Anti-MAPK therapies had broad consequences on gene expres-
sion, as quantified by hierarchical clustering of conditions based on
a similarity matrix of shared neighboring cells (Fig 6B and C). We
found that inhibition of EGFR, alone or in combination with BRAF
or MEK inhibition, was most effective in the induction of transcrip-
tome changes in the RAS/RAF-wild-type organoid lines P009T and
P013T. A combination of BRAF and EGFR inhibitors deregulated
transcriptomes effectively in the BRAF-mutant B2040 and C2019
organoids, while both inhibitors had smaller effects on their own.
As also observed for ERK phosphorylation (Fig 5C, above), these
data agree with clinical reality, where positive outcomes for EGFR
and combinatorial BRAF/EGFR inhibition are variable but limited to
patients with RAS/RAF-wild-type and BRAF-mutant CRC, respec-
tively. Effective anti-MAPK treatment contrasted with chemotherapy
in outcomes regarding transcriptome regulation and cell cycle distri-
bution in the organoids, indicating distinct mechanisms of action
(Appendix Fig S8).
Based on the above results, we concentrated on anti-EGFR, anti-
MEK, and combined anti-EGFR/BRAF inhibition for RAS/RAF-wild-
type, KRAS- and BRAF-mutant organoids, respectively, and
analyzed cell development and cell state prevalence for these
preferred inhibitor combinations. Averaging across all cells, the
MAPK-high TC1 and TC4 cell state signatures were downregulated
by the preferred treatments in all lines (Fig 6D). In P009T, P013T,
OT227, and B2040 organoid lines, the MAPK inhibitors induced
LGR5-ISC or stem cell cluster-related signatures, while OT302
showed stronger differentiation-related Goblet cell signature gene
expression (Fig 6F). To analyze whether gene expression changes
have a basis in directional cell development, we first compared
developmental trajectories, as visualized by dynamic velocities in
the UMAPs. Trajectories were re-routed to new endpoints in P013T,
OT302, and C2019 organoids under treatment and were induced in
the OT227 line that did not show directional development in the
absence of treatment (Fig 6E). Cells at the ends of trajectories
(marked in bold in Fig 6F) were distinguished from the bulk of cells
by lower differentiation-associated Goblet-like gene expression in
four out of six lines (P009T, P013T, OT302, and B2040), and the
same cells showed higher stem cell- and Wnt-associated LGR5-ISC
signature expression, or activation of Wnt targets or stem cell mark-
ers such as AXIN2 or LGR5 in some lines.
We analyzed cell state changes in detail in P013T organoids,
where EGFR inhibition induced divergent developmental trajectories
toward two distinct endpoints after 48 h of treatment (Figs 6E and
EV5). A common endpoint between control and EGFRi conditions
was characterized by goblet cell differentiation and the hallmark
apoptosis signature, whereas a new treatment-induced endpoint
was characterized by LGR5-ISC signature expression (Fig EV5A and
B). Accordingly, trajectories toward the latter endpoint showed de
novo expression of the Wnt targets AXIN2, LGR5, OLFM4 as indi-
cated by the dynamics in the phase plot after EGFR inhibition and
also by the more restricted fields of expression for the older non-
labeled as compared to the newer labeled RNAs (Fig EV5C and D).
These gene activity patterns are strong indications for the re-
routing of cell development under MAPK inhibition, away from
differentiation-associated developmental endpoints toward a state
high in expression of Wnt-driven stem cell gene expression. The
computational analyses agree with organoid culture phenotypes
showing slow outgrowth of resistant P013T colonies under long-
term EGFR treatment (Fig EV5E and F).
Discussion
Here, we provide a comprehensive analysis of patient-overarching
transcriptional states of CRC cells forming developmental trajecto-
ries. We find that cell hierarchies in CRC are organized along devel-
opmental trajectories following MAPK gradients. Our analyses
imply that CRC cells develop gradually and directional rather than
forming fixed cell populations in organoids and probably also in
patients. As cell state prevalence differed between patients, we
suggest that CRC cell trajectories are guided and constrained by indi-
vidual cancer characteristics such as paracrine signals from the
tumor microenvironment and patterns of oncogenic driver muta-
tions. Our experiments in organoids indicate that therapies targeting
the MAPK pathway reduce proliferation, but can also redirect devel-
opmental trajectories of CRC cells toward endpoints that are likely
associated with therapy resistance.
Previous single-cell studies defined features of the CRC immune
microenvironment (James et al, 2020; Lee et al, 2020; Qian et al,
2020; Zhang et al, 2020). However, no consensus exists on patient-
overarching features defining cells of the epithelial CRC
▸Figure 5. Anti-MAPK therapy affects signaling networks and transcriptomes contingent on predictive mutations in organoids.A Workflow of the experimental therapy experiment. In short, organoids were treated for 48 h with inhibitors before disaggregation into single cells for CyTOF and
scRNA-seq analysis. For scRNA-seq, organoids were labeled for 2 h with 4sU.
B Schematic representation of signaling network and transcriptional signatures associated with phenotypes or signaling pathways, as indicated.
C Heatmap of key CyTOF data. Average activities of selected analytes are given as log fold change after normalization to DMSO control condition. Range of color scale
was adjusted for each analyte. For relative changes between all analytes, see Appendix Fig S7).
D Heatmap of signature gene expression, from scRNA-seq data. Average activities of selected gene signatures are given as log fold change after normalization to DMSO
control condition. Range of color scale was adjusted for each signature. DNA repair and Apoptosis are Broad Institute Hallmark signatures.
E Correlations between and within the CyTOF and scRNA-seq datasets. For each line, average protein analyte (CyTOF) or transcriptional signature (scRNA-seq) values
were plotted for all six experimental conditions. Graphs give trend line and confidence intervals.
F Upregulation of MAPK and YAP target genes in mouse intestinal organoids after induction of oncogenic BRAF. Wnt target genes are not significantly affected. For
experimental details, see Riemer et al (2015). Graph displays data points for signature gene expression values, mean and standard deviation. ****indicates P-value of
< 0.0001 in two-tailed paired t-test of gene expression ratios (luciferase control versus BRAF-induced). n.s.: not significant.
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compartment. Here, we define six transcriptome-based states of
CRC cells, termed stem/TA-like, goblet cell-like, and TC1-4, that
have differential activities of oncogenic pathways. Individual stem
cell markers such as OLFM4 or CD44 varied in expression between
the stem/TA-cell-like and TC1-4 clusters and were also found over-
expressed in clusters of colorectal polyp and cancer cell of another
study (preprint: Becker et al, 2021). Based on these transcriptional
patterns, it appears that no unique stem cell signature exists in CRC
and that Wnt, YAP, and MAPK activities together can maintain dif-
ferent cell states that may act as functional equivalents of stem cells
that can sustain cancer growth. The TC1-4 clusters were predomi-
nantly populated by copy number-aberrant cancer cells but also
contained some non-cancerous epithelial cells. We therefore
propose that, while oncogenic signals are main drivers of the TC1-4
transcriptional states, (tumor-)microenvironmental signals and cell-
intrinsic cues can result in normal epithelial cells to assume such
transcriptional states, too.
Like many current single-cell studies, our work is limited by
rather small patient and organoid cohorts. Furthermore, our analy-
ses focused on SCN-aberrant CRC cells, and therefore, the hetero-
geneity of SCN-stable CRC, in particular MSI tumors, is not covered.
Community efforts integrating multiple studies will be required to
provide a general framework of how genetic drivers and the
microenvironment interact to direct cell state prevalence, develop-
mental trajectories, and cell plasticity during tumor progression and
under therapy. Such analyses may result in a consensus structure
for single-cell CRC transcriptomes different from the six CRC cell
cluster model proposed here.
MAPK is a key pathway for targeted therapy, as many CRC
patients profit from anti-EGFR or anti-EGFR/anti-BRAF therapy
(Amado et al, 2008; Karapetis et al, 2008; Kopetz et al, 2019). By
and large, outcomes of our experimental inhibition of MAPK in
organoids agreed with known relationships between predictive
mutations and therapy sensitivity, as EGFR inhibition was only
effective in RAS/RAF-wild-type organoids, while a combination of
BRAF and EGFR inhibitors—but not each inhibitor alone—had
profound effects on development of BRAFV600E-mutant CRC orga-
noids. In addition, we show that graded MAPK-driven gene expres-
sion informs developmental trajectories, extending previous finding
of graded ERK activity in CRC organoids (Brandt et al, 2019). Our
analyses suggest that intrinsic resistance to anti-MAPK therapies
may rely on re-routing of developmental trajectories of CRC cells.
Indeed, the ability to reverse developmental trajectories in the
intestinal epithelium has been found before (Buczacki et al, 2013;
Schwitalla et al, 2013; Jadhav et al, 2017). Our study therefore adds
new aspects to current models of anti-MAPK therapy resistance
defined by cell plasticity (Misale et al, 2014; Woolston et al, 2019;
Lupo et al, 2020).
Our study suggests that multiple signaling pathways form a
therapy-relevant interconnected network of oncogenic signaling
pathways in CRC. For instance, we find that YAP and MAPK levels
are positively correlated on the protein activity and the transcrip-
tional response levels. YAP maintains regenerative responses and is
a key driver of CRC and other cancers (Zanconato et al, 2016). In
contrast, MAPK and Wnt signaling were negatively correlated. We
and others previously showed loss of Wnt-driven intestinal stem
cells by high MAPK levels provided by oncogenic BRAF (Riemer
et al, 2015; Tong et al, 2017). Here, we find that therapeutic inacti-
vation of MAPK can result in Wnt and LGR5-ISC signature reactiva-
tion in CRC, confirming two previous studies (Zhan et al, 2019;
Lupo et al, 2020). As both pathways, Wnt and MAPK, are generally
activated by oncogenic mutations in CRC, cross-inhibition between
the pathways would mean that therapeutical suppression of one
pathway results in oncogene-driven activation of the other, possibly
explaining why many therapeutic approaches to block MAPK
proved insufficient in the clinic. It will be an important goal for
future studies to identify combinations of actionable signals that can
be exploited for therapies resulting in uniform commitment of CRC
cells to differentiation-related and apoptotic endpoints instead of re-
routing subsets of cancer cells toward stem cell-like states.
Our study also identified further cancer traits in CRC cell clusters
with relevance to therapy. For instance, TC1 cells were defined by
high levels of replication stress, which can be functionally associ-
ated with high MAPK activity (Sheu et al, 2012; Klotz-Noack et al,
2020). Tumors with high TC1 cell content were strongly positive for
PARP, an important therapeutic target (Sun et al, 2020). It is of note
that the CMS subtyping system developed for bulk tissue CRC tran-
scriptomes (Guinney et al, 2015) could not distinguish the CRC cell
types that we identified here on the single-cell level, as most epithe-
lial cancer cells were assigned to CMS1 or CMS2 with the exception
of goblet-like CRC cells that can adopt CMS3 (Appendix Fig S9).
In addition to patient-overarching CRC cell traits, we also
observed patient-specific gene expression differences. Our integrated
analysis of single-cell transcriptomes and copy number gains and
losses indicated that patient-specific gene expression patterns were
significantly associated with copy number gains that we inferred
from transcriptomes and validated using exome sequencing of three
patients. On another level, we observed patient-specific gene
◀ Figure 6. Anti-MAPK therapy re-routes developmental trajectories in CRC organoids.
A Activities of gene expression signatures, as indicated, in single-cell transcriptomes from control (DMSO) condition CRC organoids, ordered along latent time.
Correlation between cell state distributions and latent time was calculated using Pearson’s r. For correlations and significances, see Table EV6. Color code red: high
activity; blue: low activity.
B UMAPs of organoid single-cell transcriptomes, color-coded by treatment conditions, as indicated.
C Dendrograms of transcriptome similarities across treatment conditions, per organoid line. Height of dendrogram is obtained by hierarchical clustering on the overlap
of KNN neighborhoods across conditions. Preferred treatment conditions are marked by asterisk.
D Heatmap of signature gene expression, from scRNA-seq data. Average activities of gene signatures are given as log fold change for preferred treatment condition,
after normalization to DMSO control condition. Range of color scale was adjusted for each signature.
E RNA velocity analysis of organoids under DMSO and preferred treatment conditions. Latent time is given as color code in the control (DMSO) condition UMAP,
dynamical velocities are displayed as arrows.
F Scaled signature expression and single gene expression moments per cell, under control (gray) and preferred treatment (color) conditions, as indicated. 10% of cells
populating the end of latent time are displayed in bold. It is of note that latent time is linear and thus cannot capture multiple populations located at developmental
end points. Densities at the sidelines display expression in all cells.
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expression patterns that translated into regional patterns of proteins,
as evidenced by the staining for MMP7 which was confined to the
invasive front of some tumors. Such patterns of gene activity and
protein translation indicate that tumor cell development is highly
plastic and partly regulated by immune and stromal cells in the
microenvironment. Thus, we expect that the intrinsic developmental
paths of CRC cells that we observe in organoid cultures are modu-
lated by extrinsic cues from the microenvironment in vivo. Future
studies using co-cultures of different tumor-associated cell types
could disentangle key paracrine relationships in cancer.
We analyzed here primary cancer epithelium and organoid tran-
scriptomes. Novel single-cell approaches, taking into account the
diversity of the tumor microenvironment in patient cohorts stratified
by treatment, complex cell culture models, the extension of single-
cell analyses to multi-omics, and the preservation of spatial informa-
tion at a cellular level, promise to identify cellular heterogeneity and
genetic diversity of cancer at even greater detail in the future. The
combination of such approaches has the potential to improve the
molecular understanding of cancer and therapy prediction for
patients (Rajewsky et al, 2020). Our work defining developmental
trajectories of CRC contributes to this goal.
Materials and Methods
Collection and single-cell RNA sequencing of clinical specimens
Fresh normal colon and colorectal cancer tissues were acquired
during the intraoperative pathologist’s examination at Charite
University Hospital Berlin. Tissues (approx. 0.1–0.4 g) were minced
using scalpels, processed using the Miltenyi Human Tumor Dissoci-
ation Kit (Miltenyi, #130-095-929) and a Miltenyi gentleMACS
Tissue Dissociator (Miltenyi, #130-096-427), using program
37C_h_TDK_1 for 30–45 min. For three tumors, we also used diges-
tion with the cold active protease from Bacillus licheniformis (Sigma
P5380) at approx. 6°C for 45 min. with frequent agitation, following
a published protocol (Adam et al, 2017) (Appendix Fig S10). Cell
suspensions were filtered using 100 µm filters, pelleted by centrifu-
gation, treated with 1 ml ACK erythrocyte lysis buffer, washed and
resuspended in ice-cold PBS, and filtered using 20 µm filters. Debris
was removed using the Debris Removal Solution (Miltenyi #130-
109-398). Cell suspensions were analyzed for cell viability > 75%
using LIVE/DEAD Fixable Dead Cell Stain Kit (488 nm; Thermo
Fisher) and a BD Accuri cytometer. 10,000 single cells were used for
single-cell library production, using the Chromium Single-Cell 3´
Reagent Kits v3 and the Chromium Controller (10× Genomics).
Libraries were sequenced on a HiSeq 4000 Sequencer (Illumina) at
200–400 mio. reads per library to a mean library saturation of
approx. 50%. This resulted in 35,000 to 120,000 reads per cell.
DNA sequencing
For panel sequencing, DNA was extracted from FFPE tumor tissue
using the Maxwell RSC DNA FFPE Kit (Promega) or the GeneRead
DNA FFPE kit (Qiagen) and sequenced using a CRC panel (Mamlouk
et al, 2017), and/or the Ion AmpliSeq Cancer Hotspot Panel (CHP)
v2 and an IonTorrent sequencer (Thermo Fisher). Variant calling
was performed using Sequence Pilot (Version 4.4.0, JSI Medical
Systems) or SoFIA (Mamlouk et al, 2017). For exome sequencing,
DNA was isolated from fresh-frozen tumor tissue using the DNeasy
Blood and Tissue Kit (Qiagen). Exomes were sequenced using the
AllExon Human SureSelect v7 Kit (Agilent).
Histology and immunostaining
3–5 µm tissue sections of formalin-fixed and paraffin-embedded
(FFPE) tissue were used. Immunostainings were performed on the
BenchMark XT immunostainer (Ventana Medical Systems), using
CC1 mild buffer or Ultra CC1 buffer (Ventana Medical Systems) for
30 min at 100°C, and using antibodies rabbit anti-TFF3 (1:250,
Abcam, ab108599), mouse anti-FABP1 (1:1,000, Abcam, ab7366),
rabbit anti-OLFM4 (1:100, Atlas Antibodies, HPA077718), mouse
anti-EPCAM (1:100, Thermo Scientific, MS-144-P1), rabbit anti-Ki67
(1:400, Abcam, ab16667), mouse anti-Ki67 (1:50, Dako, M7240),
rabbit anti-LYZ (1:1500, Abcam, ab108508), rabbit anti-EREG (1:50,
Thermo Fischer Scientific, PA5-24727), anti-PARP1, mouse anti-
MUC2 (1:50, Leica, NCL-MUC-2), mouse anti-CK17 (1:10, Dako,
M7046), and mouse anti-MMP7 (1:100, Thermo Fisher Scientific,
MA5-14215). Images were taken using AxioVert.A1 (Zeiss) or CQ1
(Yokogawa) microscopes or scanned using the Pannoramic SCAN
150 scanner (3DHISTECH).
Organoid culture and metabolic labeling
Tumor cells were washed in Advanced DMEM/F12 medium (Gibco),
embedded in Matrigel, and cultured in 24-well plates, as published
(Sato et al, 2011). Wnt3 and R-Spondin3 were prepared as condi-
tioned media (Sato et al, 2011). For testing of media conditions, orga-
noids were re-plated four days after disaggregation into a 96-well
plate and grown in the different media (no growth factors; +EGF;
+Wnt/R-Spondin/Noggin/EGF; +AZD8931, 100 nM). After 6 days,
cell viability was measured with Real-Time-Glo MT Cell Viability
Assay (Promega, G9712) and Cyto3D Live-Dead Assay Kit (The Well
Biocioscience, BM01). NCO, P009T, and P013T replicate cultures
were cultured in media with and without Wnt/R-Spondin, and
P009T, P013T, OT227, OT302, B2040, C2019 organoids were
cultured in standard media (Sato et al, 2011; Sch€utte et al, 2017)
with DMSO or were treated for 48 with 100 nM AZD8931 (Sapatinib),
100 nM LGX818 (Encorafenib) and/or 8 µM AZD6244 (Selumetinib),
5 µM 5-fluoro-uracil or 5 µM oxaliplatin. For single-cell sequencing,
organoids were dissociated completely using TrypLE and DNAseI,
and filtered via a 20 µm filter. For single-cell SLAM-seq, organoids
were metabolically labeled in culture using 200 µM 4-thio-uridine for
2 h (Herzog et al, 2017), harvested, disaggregated to single cells by
TrypLE, and fixed in fixation buffer (80% methanol/20% DPBS) at
≥ 20°C. Samples were warmed to room temperature and incubated
with 10 mM iodoacetamide. Alkylation was carried out overnight, in
the dark, with gentle rotation, followed by two washes with cold fixa-
tion buffer. Single-cell suspensions were rehydrated and incubated
10 min at room temperature in 100 mM DTT. Samples were resus-
pended in fixation buffer and conserved at80°C.
Mass cytometry (CyTOF)
For CyTOF analysis, we used a panel of antibodies described in
Brandt et al, 2019, and measurements were performed essentially as
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in described in the same publication. In short, organoids were
harvested in PBS and digested to a single-cell solution in 1:1 Accu-
tase (BioLegend) and TrypLE (Gibco) with addition of 100 U/ml
Universal Nuclease (Thermo Scientific) at 37°C. Cells were counted,
and a maximum of 500,000 cells were stained with 5 µM Cell-ID
Cisplatin (Fluidigm) in PBS for 5 min at 37°C, washed in PBS, resus-
pended in medium and incubated for 30 min at 37°C, resuspended
in BSA/PBS solution, mixed 1:1.4 with Proteomics Stabilizer (Smart
Tube Inc.), and frozen at 80°C for storage.
For analysis, cells were thawed, mixed with Maxpar Cell Staining
Buffer (CSB, Fluidigm), labeled using the Cell-ID 20-Plex Pd Barcod-
ing Kit, and washed again in CSB, then in Barcode Perm Buffer (Flu-
idigm). After barcoding, cells were pooled and stained with a
surface antibody cocktail, as described previously (Brandt et al,
2019). Data were acquired on a Helios CyTOF system. Mass cytome-
try data were normalized using the Helios software, and bead-
related events were removed. Doublets were excluded by filtering
for DNA content (191Ir and 193Ir) vs. event length, and apoptotic
debris removed by a filter in the platin channel (195Pt). De-
convolution of the barcoded sample was performed using the CATA-
LYST R package version 1.5.3 (Chevrier et al, 2018).
Primary tissue single-cell RNA-seq data analysis
UMIs were quantified using cellranger 3.0.2 with reference tran-
scriptome GRCh38. Cell cycle was scored based on a list of cell
cycle-associated genes (Kowalczyk et al, 2015), and differences
between S and G2 M expression scores were linearly regressed out
per gene. For parameters and initial quality controls, see
Appendix Fig S2. Epithelium, stromal, and immune cells were iden-
tified by scoring cell type markers across Louvain clusters for each
sample (resolution = 1). Cell type markers used to score epithe-
lium, stromal, and immune cells were adapted from Smillie et al
(2019) and are listed in Table EV3. Sample-wise quality control
assessments and subsettings into main cell types are documented
at sys-bio.net/sccrc/. Normalized subsets were merged for each
main cell type of normal and tumor samples without further batch
correction.
SNN graph, Louvain clusters, and UMAP embeddings were
recomputed for each subset based on top ten components. Louvain
cluster-specific marker genes of merged normal and tumor samples
were used to identify sub-cell types among epithelial, stromal, and
immune subsets. Here, marker genes were determined with Seurat
(Stuart et al, 2019) at a minimum log fold change threshold of 0.25.
Gene expression sets were taken from the hallmark signature collec-
tion of the Broad institute (Liberzon et al, 2015), unless otherwise
referenced in the main text, and were scored as implemented in the
progeny R package and Seurat v3, respectively.
For copy number assessment, InferCNV v1.3.3 was used with
default parameters. Copy number-aberrant clones were cut at k = 2
in inferCNV dendrograms. Clone-wise SCNA scores were computed
by calculating the average standard deviation in inferCNV expres-
sion of all cells and divided by the average standard deviation in
inferCNV expression of all normal samples taken together. Clones
with a SCNA score greater than the highest observed score for
normal samples were considered copy number-aberrant.
For analysis of scRNA-seq validation datasets, we downloaded
publicly available data from the European Genome-phenome
Archive database (EGAS00001003779, EGAS00001003769) and
ArrayExpress (E-MTAB-8410, E-MTAB-8412; Lee et al, 2020; Qian
et al, 2020). We preprocessed data using the same pipeline as for
our primary tissue analysis, including copy number calling and
pathway activity scoring for the set of Belgian patients (KUL01-
KUL31). Additionally, we used the ingest function from scanpy to
perform linear domain adaptation for asymmetric data integration.
In short, ingest utilizes the PCA previously fitted onto our data to
transform the reference dataset into the same space. Within this
space, ingest can integrate the reference data into our UMAP coordi-
nate system (Fig EV3C) and assign reference cells into correspond-
ing cluster identities in the original dataset based on KNN classifiers
(Fig EV3D–F).
Organoid single-cell RNA-seq data analysis
Single-cell SLAM sequencing data were preprocessed using cell-
ranger v4.0, and labeled and unlabeled reads were counted using
the alignments (as BAM files), using a custom pipeline utilizing
Snakemake (Köster & Rahmann, 2012), SeqAn (Döring et al, 2008),
R. For each read, the numbers of T nucleotides and T-to-C conver-
sions were counted, leaving out positions with common SNPs (us-
ing the dbSNP build 151 as available as track from UCSC genome
browser). For each molecule as identified by cell barcode and UMI,
positions with discordant nucleotides were excluded. Subsequently,
molecules were counted as nascent RNA if they contained a T-to-C
conversion and old RNA otherwise.
scRNA-seq and scSLAM-seq data for organoids were analyzed
using scanpy (Wolf et al, 2018)and scvelo (Bergen et al, 2020). For
diffusion map analysis and RNA velocity, cells were first filtered by
the number of genes (between 2,000 and 5,000) and the percent
mitochondrial reads (between 0.075 and 0.2) and normalized, using
scvelo standard settings. Cell cycle was scored and regressed out as
for the primary cell data. UMAP embeddings were computed based
on a PCA on only the 2,000 most highly variable genes obtained
with scanpy. The similarity measure between conditions in Fig 6B
was defined by the average fraction of shared neighbors in a nearest
neighbor graph over all cells in the dataset, then performing hierar-
chical clustering on the resulting similarity matrix.
Moments were calculated on 30 principal components and 30
neighbors, separately per condition to avoid smoothing effects
between different conditions within the same dataset. Velocity was
calculated using the dynamical model from scvelo on 2,000 most
highly variable genes according to scanpy, which were then filtered
for at least 20 shared counts in both SLAM layers. Per gene, we
usually observed either induced or repressed expression dynamics
only. To resolve ambiguity in fitting kinetics to one-sided dynamics,
we modified the dynamical model from scvelo with an additional
regularization term for the experiments analyzing Wnt- versus
MAPK-driven velocity, penalizing the number of cells that are
assigned a higher latent time than a given root prior.
Ethics permission
All patients were aware of the planned research and agreed to the
use of tissue. Research was approved by vote EA4/164/19 of the
ethics commission of Charite—Universit€atsmedizin Berlin. Experi-
ments conformed to the WMA Declaration of Helsinki and to the
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principles set out in the Department of Health and Human Services
Belmont Report.
Statistical analysis
Statistical analyses of single-cell data were performed using non-
parametric Wilcox and Kruskal–Wallis tests, as indicated in main
text and figure legends. Cell state distribution statistics (Fig 4C)
were calculated using Pearson’s correlation coefficient (Pearson´s r),
and significance of correlations was assessed by t statistics
(Table EV6). Prevalence of deregulated genes in CNA genomic
regions was calculated using Bonferroni-corrected hypergeometric
distribution and human genome GRCh38 gene numbers per chromo-
some arm (Fig S4). PARP immunofluorescence (Fig 2D) and orga-
noid growth assays (Fig S6) were analyzed by unpaired t-tests. Bulk
tissue gene expression after transgene induction was analyzed by
ratio paired t-test (Fig 5F).
Data availability
Scripts for processing of patient tissue scRNA sequencing data are
available from https://github.com/molsysbio/sccrc. Scripts for
processing of organoid RNA velocity data are available from
https://github.com/molsysbio/sccrc_slamvelocity. The datasets
produced in this study are available in the following databases:
patient sequencing data GEO GSE166555 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE166555), organoid sequencing
data GEO GSE166556 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE166556). Processed count data are available from
https://sys-bio.net/sccrc.
Expanded View for this article is available online.
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Cancer cells, like normal cells in our bodies, are thought to develop
along preferred trajectories. No consensus exists how to define devel-
opmental states of colorectal cancer cells, and it is unknown which
signals control their development.
Results
We define here patient-overarching developmental states of colorectal
cancer cells and find that the cancer cells develop along trajectories
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